A Phase 1 interventional study of PF-06946860 and Placebo for PF-06946860 in Non-small Cell Lung Cancer, Pancreatic Cancer and Colorectal Cancer, sponsored by Pfizer. Completed at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-12.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 117th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2021, is one of 56 in phase 1, and was the 112th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.
A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin (subcutaneously).
During the initial 6-week treatment period (Part A), a total of 2 doses of study drug or placebo will be administered 3 weeks apart. Each dose contains two injections. Part B is an optional 18-week open-label treatment period where up to 7 doses of study drug may be administered. Part B does not include placebo.
Assessments include:
Key Inclusion Criteria:
Meets any of the following criteria at Randomization:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous injection
Drug: PF-06946860
subcutaneous injection
Drug: PF-06946860 · Drug: Placebo for PF-06946860
subcutaneous injection
subcutaneous injection
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A
The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.
Time frame: Baseline, Week 4
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A
The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score were summarized descriptively by treatment group and timepoint.
Time frame: Baseline, Weeks 1, 2, 3, 5 and 6
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A
The Cancer-Related Cachexia Symptom Assessment-Fatigue was a self-reported questionnaire that measured the severity of fatigue. The measure consisted of 1 question that asked study participants to rate their fatigue over the past 7 days from 0-"no fatigue" to 10-"worst possible fatigue", where higher score indicated worse fatigue. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Fatigue score were summarized descriptively by treatment group and timepoint.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5 and 6
Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are events between first dose of study drug and up to discharge from study that are absent before treatment or that worsen relative to pretreatment state. An SAE is any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect.
Time frame: Day 1 through Week 6 (for a period of 6 weeks)
Number of Participants With Laboratory Test Abnormalities in Part A
Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, erythrocytes mean corpuscular volume, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular hemoglobin concentration, platelets, leukocytes, lymphocytes, basophils, eosinophils and monocytes), chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate and glucose) and urine (pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes \[/high power field (HPF)\], urine leukocytes \[/HPF\] and hyaline casts \[/low power field (LPF)\]).
Time frame: Days 1, 22 and 43
| Milestone | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W |
|---|---|---|
| Started | 6 | 12 |
| Completed | 5 | 9 |
| Not completed | 1 | 3 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W |
|---|---|---|
| Started | 5 | 9 |
| Completed | 2 | 5 |
| Not completed | 3 | 4 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 |
The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.
| Units on a Scale | Placebo | PF-06946860 200mg Q3W |
|---|---|---|
| Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A | 2.45 (1.01 to 3.88) | 1.84 (0.79 to 2.90) |
The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score were summarized descriptively by treatment group and timepoint.
| Units on a Scale | Placebo | PF-06946860 200mg Q3W |
|---|---|---|
| Week 1 | 0.99 (-0.66 to 2.64) | 2.19 (1.17 to 3.20) |
| Week 2 | 1.11 (-0.03 to 2.25) | 2.21 (1.45 to 2.98) |
| Week 3 | 1.27 (-0.35 to 2.89) | 2.30 (1.20 to 3.41) |
| Week 5 | 1.95 (0.27 to 3.63) | 1.95 (0.82 to 3.08) |
| Week 6 | 2.41 (0.49 to 4.33) | 1.61 (0.32 to 2.90) |
The Cancer-Related Cachexia Symptom Assessment-Fatigue was a self-reported questionnaire that measured the severity of fatigue. The measure consisted of 1 question that asked study participants to rate their fatigue over the past 7 days from 0-"no fatigue" to 10-"worst possible fatigue", where higher score indicated worse fatigue. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Fatigue score were summarized descriptively by treatment group and timepoint.
| Units on a Scale | Placebo | PF-06946860 200mg Q3W |
|---|---|---|
| Week 1 | 1.84 (-1.47 to 5.16) | 1.52 (-0.57 to 3.60) |
| Week 2 | 0.04 (-2.71 to 2.80) | -2.12 (-3.91 to -0.34) |
| Week 3 | -1.21 (-2.33 to -0.09) | -0.49 (-1.23 to 0.25) |
| Week 4 | -1.00 (-2.40 to 0.40) | -0.55 (-1.57 to 0.48) |
| Week 5 | -0.92 (-2.47 to 0.63) | -0.24 (-1.31 to 0.82) |
| Week 6 | -1.13 (-2.40 to 0.15) | 0.74 (-0.09 to 1.57) |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are events between first dose of study drug and up to discharge from study that are absent before treatment or that worsen relative to pretreatment state. An SAE is any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect.
| Participants | Placebo | PF-06946860 200mg Q3W |
|---|---|---|
| Participants With All-Causality TEAEs | 4 | 7 |
| Participants With All-Causality SAEs | 1 | 3 |
Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, erythrocytes mean corpuscular volume, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular hemoglobin concentration, platelets, leukocytes, lymphocytes, basophils, eosinophils and monocytes), chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate and glucose) and urine (pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes \[/high power field (HPF)\], urine leukocytes \[/HPF\] and hyaline casts \[/low power field (LPF)\]).
| Participants | Placebo | PF- 06946860 200mg Q3W |
|---|---|---|
| Hemoglobin <0.8 x lower limit of normal (LLN) | 2 | 4 |
| Hematocrit <0.8 x LLN | 2 | 3 |
| Erythrocytes <0.8 x LLN | 1 | 4 |
| Erythrocytes Mean Corpuscular Volume <0.9 x LLN | 0 | 0 |
| Erythrocytes Mean Corpuscular Volume >1.1 x upper limit of normal (ULN) | 0 | 1 |
| Erythrocytes Mean Corpuscular Hemoglobin <0.9 x LLN | 0 | 1 |
| Erythrocytes Mean Corpuscular Hemoglobin >1.1 x ULN | 0 | 0 |
| Erythrocytes Mean Corpuscular Hemoglobin Concentration <0.9 x LLN | 0 | 0 |
| Erythrocytes Mean Corpuscular Hemoglobin Concentration >1.1 x ULN | 0 | 0 |
| Platelets <0.5 x LLN | 0 | 0 |
| Platelets >1.75 x ULN | 0 | 1 |
| Leukocytes <0.6 x LLN | 1 | 0 |
| Leukocytes >1.5 x ULN | 0 | 0 |
| Lymphocytes <0.8 x LLN | 2 | 6 |
| Lymphocytes >1.2 x ULN | 0 | 0 |
| Basophils >1.2 x ULN | 0 | 1 |
| Eosinophils >1.2 x ULN | 0 | 0 |
| Monocytes >1.2 x ULN | 0 | 1 |
| Bilirubin >1.5 x ULN | 0 | 0 |
| Aspartate Aminotransferase >3.0 x ULN | 0 | 0 |
| Alanine Aminotransferase >3.0 x ULN | 0 | 0 |
| Alkaline Phosphatase >3.0 x ULN | 0 | 2 |
| Protein <0.8 x LLN | 1 | 0 |
| Protein >1.2 x ULN | 0 | 0 |
| Albumin <0.8 x LLN | 0 | 0 |
| Albumin >1.2 x ULN | 0 | 0 |
| Blood Urea Nitrogen >1.3 x ULN | 0 | 0 |
| Creatinine >1.3 x ULN | 0 | 1 |
| Urate >1.2 x ULN | 0 | 0 |
| Sodium <0.95 x LLN | 0 | 0 |
| Sodium >1.05 x ULN | 0 | 0 |
| Potassium <0.9 x LLN | 0 | 0 |
| Potassium >1.1 x ULN | 0 | 0 |
| Chloride <0.9 x LLN | 0 | 0 |
| Chloride >1.1 x ULN | 0 | 0 |
| Calcium <0.9 x LLN | 0 | 0 |
| Calcium >1.1 x ULN | 0 | 0 |
| Bicarbonate <0.9 x LLN | 1 | 1 |
| Bicarbonate >1.1 x ULN | 0 | 0 |
| Glucose <0.6 x LLN | 0 | 0 |
| Glucose >1.5 x ULN | 1 | 2 |
| pH <4.5 | 0 | 0 |
| pH >8 | 0 | 0 |
| Urine Glucose >=1 | 0 | 1 |
| Ketones >=1 | 0 | 0 |
| Urine Protein >=1 | 2 | 0 |
| Urine Hemoglobin >=1 | 0 | 2 |
| Urobilinogen >=1 | 0 | 0 |
| Urine Bilirubin >=1 | 0 | 0 |
| Nitrite >=1 | 0 | 1 |
| Leukocyte Esterase >=1 | 1 | 2 |
| Urine Erythrocytes (/HPF) >=20 | 0 | 1 |
| Urine Leukocytes (/HPF) >=20 | 0 | 1 |
| Hyaline Casts (/LPF) >1 | 0 | 2 |
Collected over Part A: Day 1 through Week 6 Part A + Part B: up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/6 (16.7%) | 1/6 (16.7%) | 4/6 (66.7%) |
| PF-06946860 200mg Q3W | 2/12 (16.7%) | 3/12 (25%) | 4/12 (33.3%) |
| Placebo -> OL PF-06946860 200mg Q3W | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W | 4/12 (33.3%) | 5/12 (41.7%) | 8/12 (66.7%) |
| Event | Placebo | PF-06946860 200mg Q3W | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 1/6 | 0/12 | 1/6 | 0/12 |
| Disease progressionGeneral disorders | 0/6 | 0/12 | 1/6 | 2/12 |
| HypokalaemiaMetabolism and nutrition disorders | 1/6 | 0/12 | 1/6 | 0/12 |
| Acute myocardial infarctionCardiac disorders | 0/6 | 1/12 | 0/6 | 1/12 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/6 | 1/12 | 0/6 | 1/12 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/6 | 1/12 | 0/6 | 1/12 |
| Event | Placebo | PF-06946860 200mg Q3W | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/6 | 0/12 | 2/6 | 0/12 |
| FallInjury, poisoning and procedural complications | 1/6 | 0/12 | 2/6 | 0/12 |
| Urinary tract infectionInfections and infestations | 1/6 | 3/12 | 1/6 | 3/12 |
| Ocular hyperaemiaEye disorders | 0/6 | 0/12 | 1/6 | 0/12 |
| Abdominal pain lowerGastrointestinal disorders | 0/6 | 0/12 | 1/6 | 0/12 |
| NauseaGastrointestinal disorders | 0/6 | 1/12 | 1/6 | 2/12 |
| VomitingGastrointestinal disorders | 0/6 | 1/12 | 0/6 | 2/12 |
| FatigueGeneral disorders | 0/6 | 0/12 | 1/6 | 1/12 |
| Gait disturbanceGeneral disorders | 0/6 | 0/12 | 1/6 | 0/12 |
| OedemaGeneral disorders | 0/6 | 0/12 | 1/6 | 0/12 |
The baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.
| Age, Continuous(Years) | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W | Total |
|---|---|---|---|
| Mean | 68.0 ± 7.95 | 74.0 ± 9.12 | 72.0 ± 8.99 |
| Age, Customized(Participants) | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W | Total |
|---|---|---|---|
| <18 | 0 | 0 | 0 |
| 18-44 | 0 | 0 | 0 |
| 45-64 | 2 | 2 | 4 |
| >=65 | 4 | 10 | 14 |
| Sex: Female, Male(Participants) | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W | Total |
|---|---|---|---|
| Female | 2 | 5 | 7 |
| Male | 4 | 7 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 5 | 11 | 16 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo -> OL PF-06946860 200mg Q3W | PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W | Total |
|---|---|---|---|
| White | 3 | 11 | 14 |
| Black or African American | 3 | 0 | 3 |
| Asian | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from May 2021 to primary completion in Apr 2022, 11 months.
Results were first posted in Jan 2024, 1 year 8 months after primary completion.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 11 months is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponsegromab
Carcinoma, Non-Small-Cell Lung →